Objective: Serum Retinol Binding Protein 4 (RBP4) is a new liver-and adipocyte-derived signal that may contribute to insulin resistance. Therefore, the RBP4 gene represents a plausible candidate gene involved in susceptibility to type 2 diabetes mellitus (T2DM).
Serum Retinol Binding Protein 4 (RBP4) is a new adipocyte-derived signal linking adipose tissue dysfunction to systemic insulin resistance and thereby, likely contributing to the pathogenesis of type 2 diabetes mellitus (T2DM). Serum RBP4 is elevated in insulin-resistant mice as well as humans with obesity and T2DM, and can be normalized by insulin sensitising drugs (1) . Moreover, RBP4 serum levels highly correlate with the degree of insulin resistance in subjects with obesity, impaired glucose tolerance or T2DM, as well as in non-obese subjects with family history of T2DM (2) . Recently, we found increased RBP4 mRNA expression in visceral as compared to subcutaneous adipose tissue and serum RBP4 concentrations correlated with RBP4 mRNA expression, intraabdominal fat mass, total body fat mass, HbA 1 c and insulin resistance (3) .
RBP4 is encoded by RBP4 gene which maps to chromosome 10q23-q24, a region that has been linked to increased risk for T2DM in different populations (4, 5) . Despite known physiology as well as chromosomal location, to date, only few studies on effects of genetic variation in the RBP4 on increased metabolic risk in humans have been reported (6, 7) . We therefore investigated whether genetic variants within the RBP4 might be responsible for observed changes in RBP4 mRNA expression and whether it might affect obesity/T2DM and pathophysiologically relevant traits in humans. We screened the gene for prevalent and functionally relevant variants and genotyped six informative SNPs in 934 patients with T2DM and 716 healthy German Caucasian subjects. To identify genetic variants, all 6 exons (NCBI reference-NM_006744), including intron/exon splicing sites, the 5' region (~1500 bp upstream of the first translation initiation site, which also included the 5' UTR (exon 1 and the part of exon 2) and the intron 1) and the 3' untranslated region (UTR) were sequenced in DNA samples from 48 non-related Caucasian subjects (24 non-diabetic with normal glucose tolerance and 24 subjects with T2DM). Eight SNPs (5 novel and 3 known database SNPs) were identified ( Figure 1 ). Three SNPs were in the 5' region and 5 SNPs were in introns. Based on recent publication(7), we selected 5 additional SNPs (rs36014035, rs12265684, rs34571439, rs12766992 and rs10882273) with MAF>5% in Caucasian samples (7) , which were genotyped in 90 subjects including all 48 sequenced DNA samples.
We Figure 1 ). For association studies, only c.248+44T>C, rs3758539, rs12265684 and rs10882273 were selected as representative variants for all 4 L.D. groups and genotyped in all subjects for association analyses. In addition, rs3758538 and rs10882283, which were unique among SNPs were also selected for further association analyses. The genotype distributions for all SNPs were consistent with Hardy-Weinberg equilibrium.
Using the PHASE v.2.1 software(9,10), we identified 5 common haplotypes among the 6 different SNPs genotyped in all subjects (Table 1) . These 5 
, it is not surprising that subjects carrying the [A-G-G-T-G-C] had significantly higher mean fasting plasma insulin and 2-h plasma glucose compared with subjects without the haplotype (Table 3) , which further supports the observed association with T2DM. We are aware that we have not corrected our statistical analyses for the number of comparisons made (given the number of tested traits and 6 SNPs) and the results need to be interpreted with caution. However, our data strongly support the findings reported by Craig et al., who investigated the RBP4 and its role in T2DM in 2 Caucasian cohorts (Utah and Arkansas) and in individuals of African American ancestry (7) . Similarly to our present study, they showed significant effects of RBP4 genetic variation on insulin resistance in Caucasians. In addition, one haplotype was significantly increased in subjects with T2DM, so the authors suggest that noncoding variants may increase diabetes susceptibility and may contribute to insulin resistance (7) . Although the haplotype composition in our present study was extended by 2 additional variants (rs3758538 and rs10882283), the [A-G-G-T-G-C] haplotype corresponds to the diabetes risk haplotype described by Craig et al. (7) . Thus our findings provide further independent evidence for the involvement of RBP4 variants in susceptibility to T2DM.
Interestingly, circulating serum FFA concentrations were significantly associated with three SNPs (Table 2 ). These effects were reflected in the haplotype analysis where the [A-A-G-T-C-C] haplotype was associated with elevated FFA levels ( Table  3) . Our findings are consistent with recently reported data from RBP4 knockout mice (1) . It has been shown that genetic deletion of RBP4 in Rbp4-/-knockout mice results in lower levels of serum FFAs, which was suggested to be linked to their improved insulin sensitivity. However, FFAs were not changed in insulin-resistant transgenic mice with overexpressed RBP4, in RBP4-injected mice or in adipose-Glut4-/-mice, suggesting that regulation of circulating FFA levels does not seem to be the principal mechanism by which RBP4 regulates insulin sensitivity (1) . Nevertheless, we believe that the association of FFAs with RBP4 SNPs, together with the data from RBP4-/-knockout mice manifesting lower levels of serum FFAs provokes further studies aimed to pinpoint the mechanisms by which RBP4 might alter circulating levels of FFA.
Increased RBP4 expression in visceral adipose tissue is a likely source for elevated RBP4 serum concentrations in patients with increased visceral fat mass and T2DM and could therefore contribute to mechanisms linking visceral fat accumulation to the development of insulin resistance(3). Therefore, we examined whether genetic variants could affect RBP4 mRNA expression in visceral and subcutaneous fat as well as serum RBP4 concentrations. Although we found no significant impact of the single variants on either visceral and subcutaneous mRNA expression or on serum RBP4 (Online Supplement- Considering the association of this haplotype with T2DM and related traits, it is noteworthy that visceral RBP4 mRNA levels was the strongest factor significantly affecting glucose infusion rate in a multivariate generalized linear model analysis also including age, sex, BMI, WHR and % body fat (data not shown). This suggests a role of RBP4 genetic variation in susceptibility to insulin resistance, possibly through an effect on RBP4 expression. Regarding the lack of statistically significant genetic association with serum RBP4 concentrations, we need to point out that this subgroup of subjects had a high mean BMI (30.0±6.9 kg/m 2 ) which may have masked the effect of genetic variants on serum RBP4 levels.
Two identified SNPs (rs3758538,rs3758539) are located 5' upstream of the translation start site in a putative promoter region. We therefore used the Transcription Element Search System (TESS; URL:http://www.cbil.upenn.edu/tess) to examine transcriptional regulatory sequences surrounding these genetic variants, which might modify RBP4 expression. The highly conserved region surrounding rs3758539 matches human transcriptional binding sites for MAZ (11) and R1/R2/Sp1 for the major allele G(12,13) and c-Ets-2 for the minor allele A (14) . Furthermore, this SNP seems to influence the transcription efficiency in a hepatocarcinoma cell line as well as the binding efficiency of hepatocyte nuclear factor 1 alpha to the motif (6) . Regarding the association of RBP4 haplotype with mRNA levels, this also indicates a potential functional relevance of the noncoding RBP4 variants in the putative promoter region. However, only additional functional experiments on these SNPs might definitely assign causality for the associated phenotypes. Alternatively, the RBP4 haplotypes might harbour a variant, which controls RBP4 mRNA levels but was not tested in our present study as only exons and potentially regulatory regions were sequenced.
In conclusion, consistent with previously reported findings in mice and in human studies (1, 6, 7) , several RBP4 SNPs and their haplotypes are likely to affect measures of insulin resistance (fasting plasma insulin, 2-h plasma glucose) and related traits (BMI, WHR and circulating FFAs) as well as RBP4 mRNA levels in visceral adipose tissue in humans. These effects may ultimately result in T2DM, which is in line with observed association of the [A-G-G-T-G-C] haplotype with increased risk of T2DM in the present study. Thus, our data indicate a role of RBP4 genetic variation in susceptibility to T2DM and insulin resistance, possibly through an effect on RBP4 expression.
RESEARCH DESIGN AND METHODS

Experimental subjects
Nine hundred and thirty-four patients with T2DM and 716 healthy subjects were recruited at the University Hospital in Leipzig, Germany. The healthy subjects included 269 males and 447 females (mean age 47.2±14.6 years, mean body mass index (BMI) 27.4±5.3, mean waist-to-hip ratio (WHR) 0.96±0.19) and patients with T2DM included 477 males and 457 females (mean age 64.5±10.8 years, mean BMI 29.6±5.0, mean WHR 1.13±0.13)(the data represent mean±S.D.). In addition, oral glucose tolerance test (OGTT) and fasting plasma insulin measurements were performed in all non-diabetic subjects as described elsewhere (15) . One hundred seventy-nine out of 716 subjects had impaired glucose tolerance. Since impaired glucose tolerance is a T2DM predicting factor, only the remaining 537 subjects with normal glucose tolerance were included as healthy controls in the T2DM case-control study. In a subgroup of 403 non-diabetic subjects, body fat content was measured by dual Xray absorptiometry (DEXA). Insulin sensitivity was assessed with the euglycemic, hyperinsulinemic clamp method as previously described(16,17). In addition, paired samples of visceral and subcutaneous adipose tissue were obtained from a subgroup of 218 Caucasian men (N=108) and women (N=110), who underwent open abdominal surgery for gastric banding, cholecystectomy, weight reduction surgery, abdominal injuries, or explorative laparotomy (described in detail elsewhere)(18). The age ranged from 23 to 99 years and body mass index from 20.8 to 54.1 kg/m 2 . In these subjects, serum RBP4 concentrations were also measured. Only non-diabetic subjects (N=170) were included in association analyses. All studies were approved by the ethics committee of the University of Leipzig and all subjects gave written informed consent before taking part in the study.
Measurement of serum RBP4
RBP4 was measured in serum by ELISA (ALPCO) or by quantitative Western blotting with purified human RBP4 standards as described in detail elsewhere (2) .
Analysis of human RBP4 expression
Human RBP4 mRNA expression was measured by quantitative real-time PCR in a fluorescent temperature cycler using the TaqMan assay, and fluorescence was detected on an ABI PRISM 7000 sequence detector (Applied Biosystems, Darmstadt, Germany), as described in detail elsewhere (3, 19) .
Sequencing of the RBP4
Sequencing of the RBP4 was performed using the Big Dye Terminator (Applied Biosystems, Inc.) on an automated DNA capillary sequencer (ABI PRISM 3100 Avant; Applied Biosystems Inc.). Sequence information for all oligonucleotide primers used for variant screening is available upon request.
Genotyping of RBP4 SNPs
Genotyping of selected SNPs in all study subjects was done using the TaqMan assay (Applied Biosystems, Inc.) for the variants rs3758538,rs3758539,c.248+44T>C,rs1226 5684, rs10882273 and by restriction fragment length polymorphism (RFLP) technique for the SNP rs10882283. Oligonucleotide sequences are available upon request. The TaqMan genotyping reaction was performed according to the manufacturer's protocol on an ABI PRISM 7000 or ABI PRISM 7700 sequence detector (Applied Biosystems Inc.). The RFLP genotypes were determined by PCR amplification of the respective fragments from exon 1 of the RBP4 on a GeneAmp PCR system 9700 (95˚C for 5 min, and 95˚C for 30 sec, and 60˚C for 1 min, 72˚C for 30 sec for 35 cycles, and 72˚C for 10 min) and subsequent digestion with the SchI (Fermentas life sciences) restriction enzyme and size fractionation and visualization by electrophoresis. To assess genotyping reproducibility, a random ~10% selection of the sample was re-genotyped in all four SNPs; all genotypes matched initial designated genotypes.
Statistical analyses
Prior to statistical analysis, nonnormally distributed parameters were logarithmically transformed to approximate a normal distribution. Differences in genotype frequencies between the diabetic cases and healthy controls were compared using logistic regression and differences in haplotype frequencies were compared using the chi square test. Multivariate linear relationships were assessed by generalized linear regression models. P-values<0.05 were considered to be of statistical significance and are presented without correction for multiple hypothesis testing. Based on minor allele frequencies in the present study, we had >85% power (α=0.05) to detect a difference in allele frequency of 6-9%, corresponding to an OR of 1.5-1.9; hence, smaller effects were likely to be missed. The analysis of associations with RBP4 serum concentrations and mRNA in adipose tissue was restricted to nondiabetics to avoid diabetes status masking potential effects of the variants on these phenotypic traits. Although we performed separate analyses also in subjects with T2DM only, no associations with above mentioned parameters were found. This is most likely due to lacking statistical power in this very small sample size and given the very low haplotype frequencies. Therefore, these data are not shown in the manuscript. Statistical analyses were performed using the SPSS software package (SPSS, Inc.; Chicago, IL) and the statistical analysis system of the SAS Institute (Cary, North Carolina, USA). Haplotype frequencies were compared using the chi square test; OR (95 % CI) -odds ratio with 95% confidence intervals. Haplotypes are defined by the composition of alleles at each SNP in following order: The data are presented as arithmetic means ± S.E.M. for normal variables (age and fasting plasma glucose) and geometric means (95% CI) for nonnormally distributed variables. P values were calculated after adjusting for age and sex for the variable BMI, WHR and % body fat and age, sex and BMI for the variables fasting plasma glucose, fasting plasma insulin, 2-hr plasma glucose, glucose infusion rate, HbA 1C and free fatty acids. In the additive model, homozygotes for the major allele (MM), heterozygotes (Mm) and homozygotes for the minor allele (mm) were coded to a continuous numeric variable for genotype (as 0, 1, 2). A dominant model was defined as contrasting genotypic groups MM+Mm vs. mm, and the recessive model was defined as contrasting genotypic groups MM vs. Mm+mm. # (+,*) indicates P<0.05 in additive (dominant, recessive) mode of inheritance and ## (++,**)indicates P<0.01 in additive (dominant, recessive) mode of inheritance. Due to the low frequency of the rare allele in rs3758538 and c.248+44T>C, for statistical analysis the homozygotes for minor alleles were combined with the heterozygotes and therefore, only a dominant effect on risk has been tested for the rare allele for glucose infusion rate and % body fat. 
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